Allogene Therapeutics' Cemacabtagene Ansegedleucel Receives FDA's Regenerative Medicine Advanced Therapy, Fast Track Designations To Treat B-Cell Lymphoma
Allogene Therapeutics Inc ALLO
$1.88
▼ -4.57%
($-0.09)
🔥 High Short Interest
🗓️ Earnings Next Week
Open
$1.97
Prev Close
$1.97
Day Range
$1.86 – $2.00
52W Range
$0.98 – $4.46
Market Cap
$648.89M
Beta
0.46
EPS (TTM)
$-0.87
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-10-11 |
| Shares Out. | 345,150,000 |
| Website | allogene.com/ ↗ |
| Phone | 16504572700 |
| Employees | 152 |
| Net Income | -$42.6M |
| Free Cash Flow | -$109.5M |
| Total Assets | $396.0M |
| Total Liabilities | $117.1M |
| Equity | $278.9M |
About Allogene Therapeutics Inc
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
Allogene Therapeutics Inc is a publicly traded company under the ticker symbol ALLO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
19 analysts (2026-07-01)